Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to enable the provision of support for AIDS Malignancy Consortium (AMC).
AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas:
Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical trials; Management of issues of international importance in HIV associated-malignancies; and Distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource (ACSR) for ongoing or future investigations.
The AMC must consist of the following functional units:
a Coordination Center; Clinical Trial Sites; Network Laboratories; and a Statistical Center.
The AMC team must have scientific disease-oriented Working Groups to study Kaposi Sarcoma, Hematologic Malignancies , Human papilloma virus-associated cancers, and Solid Tumors in people with HIV.
The Network Laboratories will be responsible for routine clinical trial support activities, pathogenesis-driven correlative studies, and clinical pharmacology and pharmacokinetics studies of anticancer/antiviral interactions.
All clinical trials to be conducted by the AMC must be available to subjects of all racial/ethnic groups.
AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas:
Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical trials; Management of issues of international importance in HIV associated-malignancies; and Distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource (ACSR) for ongoing or future investigations.
The AMC must consist of the following functional units:
a Coordination Center; Clinical Trial Sites; Network Laboratories; and a Statistical Center.
The AMC team must have scientific disease-oriented Working Groups to study Kaposi Sarcoma, Hematologic Malignancies , Human papilloma virus-associated cancers, and Solid Tumors in people with HIV.
The Network Laboratories will be responsible for routine clinical trial support activities, pathogenesis-driven correlative studies, and clinical pharmacology and pharmacokinetics studies of anticancer/antiviral interactions.
All clinical trials to be conducted by the AMC must be available to subjects of all racial/ethnic groups.
Related Programs
Department of Health and Human Services
Department of Health and Human Services
Cancer Cause and Prevention Research
Department of Health and Human ServicesCancer Detection and Diagnosis Research
Department of Health and Human ServicesDepartment of Health and Human Services
Department of Health and Human Services
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $0
Office: National Institutes of Health
Estimated Funding: $0
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-028.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are not eligible to apply.
See full Notice of Funding Opportunity Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-028.html
Contact:
Agency Email Description:
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Agency Email:
Date Posted:
2024-08-13
Application Due Date:
Archive Date:
2025-02-15
Social Entrepreneurship
Spotlight
New Study Finds Social Enterprises Help Support 2.5M Poor Filipinos
A latest study, called “Poverty Reduction and Women Economic Leadership: Roles, Potentials and Challenges of Social Enterprises in Developing Countries in Asia,†which covers countries like Bangladesh, Indonesia, and the Philippines, about 2.5 million Filipinos are covered by social enterprises in the Philippines.
Learn How to Identify and Avoid Grant Scams
